Bed Bath & Beyond (BBBY) opened Q1 2026 with revenue of US$247.8 million and a basic EPS loss of US$0.24, as investors weigh another quarter of negative earnings against the broader story around the business. The company reported quarterly revenue of US$231.7 million in Q1 2025 and US$247.8 million in Q1 2026, while basic EPS over that span has ranged from a loss of US$0.74 to a loss of US$0.24. This frames an earnings picture where the key question is how much longer margins remain negative.
See our full analysis for Bed Bath & Beyond.With the latest numbers on the table, the next step is to compare this earnings profile with the narratives investors follow around growth potential, risks and the path back toward healthier margins.
See what the community is saying about Bed Bath & Beyond
Losses Still Heavy On A Bigger Revenue Base
- Over the trailing 12 months, Bed Bath & Beyond generated US$1.1b of revenue but recorded a net loss of US$61.1 million, and over the last five years losses have grown at about 54.6% per year.
- Bulls focus on the idea that revenue scale and mix can eventually carry earnings, yet the latest numbers highlight the tension:
- Q1 2026 revenue of US$247.8 million sits within a US$1.1b trailing revenue base, but the company still posted a Q1 net loss of US$16.4 million and a trailing 12 month loss of US$61.1 million.
- The bullish view that margin improvement is a key lever has to reckon with the fact that the business remains loss making and is expected to stay unprofitable over the next three years.
Strong revenue scale with ongoing losses is exactly what bulls and bears are debating, so it is worth seeing how bullish investors connect this earnings profile to their thesis in more detail 🐂 Bed Bath & Beyond Bull Case.
Valuation Looks Cheap Next To Peers
- The shares trade on a P/S of 0.4x versus a peer average of 4x and an industry average of 0.5x, while the current price of US$4.74 is well below the referenced DCF fair value of US$41.37.
- Consensus narrative points to this discount as a potential upside source, but the earnings track record pulls the other way:
- Trailing 12 month revenue growth of 4.8% a year is slower than the cited 11% a year for the broader US market, which helps explain why a low 0.4x P/S multiple may persist.
- The same dataset shows ongoing losses over the past year, so the large gap between the share price and the DCF fair value relies on the business eventually turning negative margins into positive earnings.
Growth Pace Trails Market While Losses Persist
- Revenue growth of 4.8% a year over the last 12 months sits below the 11% a year reference rate for the US market, and forecasts indicate the company is not expected to return to profitability within the next three years.
- Bears lean on these trends to argue that the story is still high risk despite the low multiples:
- The trailing 12 month loss of US$61.1 million follows several years where losses grew at about 54.6% each year, which is consistent with bearish concerns about earnings not yet stabilizing.
- Recent shareholder dilution over the past year aligns with the bearish view that funding ongoing losses may continue to rely on issuing equity, which matters for anyone watching per share outcomes.
If you are weighing that bearish view against the low valuation, it helps to see how cautionary investors frame these risks in full context 🐻 Bed Bath & Beyond Bear Case.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Bed Bath & Beyond on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
On balance, do you feel this story leans more bullish or bearish right now, and what matters most to you in that trade off? The quickest way to check the full picture for yourself is to review the 1 key reward and 2 important warning signs.
See What Else Is Out There
Ongoing losses, slower 4.8% revenue growth versus the 11% market reference, and shareholder dilution all point to a business profile with elevated risk.
If you want alternatives with less earnings pressure and potentially steadier profiles, check out the 73 resilient stocks with low risk scores to quickly compare companies built around lower risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com